BCTX briacell.com Accounting Capitalization

This price chart for BriaCell Therapeutics (BCTX) on the GURU.Markets platform reflects the performance of a company developing personalized vaccines based on the Bria-IMT system to combat breast metastases. The current indicator stands at 0.03. The high risk associated with a narrow development portfolio is mitigated by accelerated approval from US regulators. The technology prompts the body to perceive the neoplasm as a virus, eradicating the disease without the use of aggressive chemotherapy.

BCTX BriaCell Therapeutics Corp Book Capitalization (07/04/2022 - 10/28/2026)

Financial and market metric breakdowns for BriaCell (BCTX)

- price and consensus price forecast:

Price BriaCell Corp|BCTX - Consensus Target

- market capitalization data:

Market Capitalization BriaCell Therapeutics Corp.|BCTX - Enterprise Value

- book capitalization data:

Accounting Value per Share BriaCell|BCTX - Book Capitalization|Market Capitalization to Book Value Ratio briacell.com|BCTX - Aggregate Company Assets

- debt and liquidity data:

Debt to Equity Ratio BriaCell Therapeutics|BCTX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio BriaCell Therapeutics Corp.|BCTX - Company Aggregate Debts|Debts to Book Value BriaCell Therapeutics Corp.|BCTX - Company Long-Term Debt|Company Short-Term Loans and Borrowings BriaCell

Summary company analysis:BriaCell Corp - BCTX

Mass-produced product of BriaCell Therapeutics Corp

The humanitarian status of BriaCell Therapeutics (BCTX) developments in breast cancer therapy provides the company with legal stability and protection against geopolitical risks. By analyzing the capital volume in the balance sheet reports, an investor sees the asset value stripped of speculation, which serves as the foundation for assessing the issuer's real resilience during periods of market volatility, determining the fair value threshold of the business.

Competitors of BriaCell Therapeutics